CDT Equity Stockholders Approve All Proposals, Positioning the Company for Growth

CDT Equity Inc. shareholders have approved all proposals at a special meeting, positioning the company for growth. The company is set to transform with a $123M investment in Sarborg, expansion of its IP portfolio, potential new capital access, and an annual overhead of less than $8 million. CDT's use of AI and algorithmic approach enables disease analysis in hours, a breakthrough in drug re-purposing. The company is now moving to out-license deals with disease-specific partners and funds.